Eisai Opts to Codevelop Biogen’s Aducanumab; New MS Copromotion Scheme Sealed

Eisai and Biogen are expanding their Alzheimer’s disease collaboration, with the Japanese major exercising its option to jointly develop and commercialize the US biotech’s investigational anti-amyloid beta (Aβ) antibody aducanumab, the two companies said on October 23. The Japanese pharma...read more